Cytomegalovirus (CMV) is a potential complication after stem cell transplantation. Normally, CMV may cause a mild infection that goes away without treatment. But CMV infection can be more serious after stem cell transplantation, when patients’ immune systems are weakened.
The purpose of this study is to assess the effectiveness of a new antiviral drug called CMX001 for preventing CMV infection in recipients of stem cell transplants who show evidence of previous CMV infection. Patients in this study will be randomly assigned to receive either CMX001 or a placebo (sugar pill). CMX001 is taken orally (by mouth).